The present invention relates to :* combinations of :component A: one or more 2,3-dihydroimidazo[1,2-c]quinazoline compounds of general formula (A1) or (A2) as defined herein, or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof component B : one or more IRAK4-inhibiting compounds of general formula (I) as defined herein,or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof in which optionally some or all of the components are in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially.dependently of one another by the oral, intravenous, topical, local installations, intraperitoneal or nasal route * use of such combinations for the preparation of a medicament for the treatment or prophylaxis of a cancer and* a kit comprising such a combination.
